Skip to main content
Medical Reference · Condition Monograph

Non-Hodgkin Lymphoma

비호지킨임파선암

A broad category that groups the many lymphomas arising from lymphocytes. Because the rate of progression and the treatment differ greatly by subtype, accurately classifying the "subtype" rather than the "disease name" is the starting point for understanding it.

History

Non-Hodgkin lymphoma is a collective term for cancers that begin in lymphocytes (the white blood cells responsible for immunity), and it is a broad category that groups many different lymphomas together rather than "a single disease." A point that the general public easily finds confusing is that even within the same non-Hodgkin lymphoma, some people progress slowly while others worsen rapidly; this is because different subtypes (specific kinds) are in fact mixed together. In the past, it was difficult to divide diseases with swollen lymph nodes and systemic symptoms as finely as we do now. In the era when classification was based only on the shape of cells seen under the microscope, different diseases were sometimes grouped under the same name, and the same disease was sometimes called by different names depending on the researcher or country.

Later, as pathology and immunology developed, lymphomas came to be broadly divided into "Hodgkin lymphoma" and other lymphomas, and the various lymphomas that do not fall under Hodgkin lymphoma came to be collectively called non-Hodgkin lymphoma. However, because the range of "other" was so broad, a key task of modern medicine was to accurately subdivide non-Hodgkin lymphoma into multiple subtypes. As it became clear that treatment response and prognosis differ greatly depending on which immune cell the cancer cells originated from (typically B cells or T cells), the protein markers on the cell surface, and chromosomal and genetic changes, classification became increasingly refined.

The development of treatment also moved together with this history of classification. At one time chemotherapy was central, but outcomes later improved as immunotherapy was added, and with the emergence of targeted therapy, treatment shifted toward "choosing a drug better suited to each subtype." Recently, advanced treatments that use immune cells themselves, such as chimeric antigen receptor T-cell (CAR-T) therapy, have also become an option.

Ultimately, the key to summarizing the historical trend is that "we have moved from an era of viewing it as one broad category to an era of accurately classifying subtypes and providing tailored treatment." For this reason, the starting point for understanding non-Hodgkin lymphoma today is the "subtype" even more than the "disease name," and subtype classification is very important in the diagnostic process.

Causes

Non-Hodgkin lymphoma is rarely explained by a single cause, such as one specific bacterium or one specific food. In most cases, it is understood that several risk factors overlap, genetic damage accumulates in lymphocytes, and some of those cells escape the body's control and keep multiplying, progressing to cancer. In other words, it is more accurate to view the cause not as "a single event" but as a process in which several conditions that can raise the risk overlap. Also, having a risk factor means the likelihood is higher; it does not mean the disease will necessarily develop.

The most widely known major axis is weakened immune function. The immune system not only prevents infection but is also responsible for monitoring and eliminating abnormal cells. Therefore, when immunity weakens, abnormal lymphocytes survive more easily. The risk can increase in situations in which the immune system is impaired, such as long-term use of immunosuppressants after organ transplantation, congenital immunodeficiency, or human immunodeficiency virus (HIV) infection.

Certain infections are also associated with some subtypes. Epstein–Barr virus (EBV) can be linked to the development of some lymphomas, and Helicobacter pylori (H. pylori) is known to be associated with mucosa-associated lymphoid tissue (MALT) lymphoma arising in the stomach. In addition, in conditions with persistent chronic inflammation, such as autoimmune diseases like rheumatoid arthritis and Sjögren's syndrome, lymphocytes are stimulated for a long time and proliferate repeatedly, which increases the likelihood that genetic "mistakes" will accumulate.

Environmental factors cited include exposure to some chemicals (pesticides, organic solvents, etc.) and radiation exposure, but at the individual level it is mostly difficult to conclude that "this exposure is the direct cause." The realistic message is that if you have an immunocompromised state or a chronic infection or inflammatory condition, responding more sensitively to changes and being evaluated early when unexplained symptoms persist helps reduce the risk.

Genetic Epidemiology

Non-Hodgkin lymphoma is usually not a hereditary disease that is "passed down directly" in families. There are studies suggesting that the risk may be slightly higher when a family member has had lymphoma or certain blood cancers, but this may reflect some genetic predisposition, or it may be that the environment and infection exposures shared by the family and the distribution of immune-related diseases acted together. Therefore, having no family history does not mean you can be reassured, and having a family history does not mean the disease will necessarily develop.

The more central "genetics" in non-Hodgkin lymphoma is the genetic changes acquired within the cancer cells. Lymphocytes divide repeatedly in response to infection, and B cells in particular go through a process of rearranging their genes to produce antibodies. This is normally precisely regulated, but when a mistake rarely occurs, part of a chromosome may move to another chromosome (translocation), or changes may occur in which specific genes are excessively switched on or off.

For example, if a gene that prevents cells from dying (such as BCL2) becomes overactive, the abnormal cells' "ability to survive without disappearing" can become stronger, and if a gene that makes cells divide quickly (such as MYC) becomes overactive, the "rate of proliferation" can increase. These molecular features also help explain why, even within the same non-Hodgkin lymphoma, some subtypes progress slowly while others progress very rapidly.

In modern diagnosis, these changes are identified through immunohistochemistry together with genetic and chromosomal tests (e.g., fluorescence in situ hybridization (FISH)), with the aim of accurately classifying the subtype. This is not merely "to identify the cause" but because it helps in planning treatment strategy and predicting the risk of relapse.

At the population level, there may be a tendency for certain subtypes to be more common in certain regions, or for subtypes associated with certain infections to be observed more often, and this is the result of a combination of genetic background, infection exposure, access to diagnosis, and other factors. In this sense, it is good to understand genetic epidemiology as including not only "family history" but also "genetic changes inside cancer cells and population patterns."

General Epidemiology

Non-Hodgkin lymphoma is a relatively common blood cancer that accounts for a large share of lymphomas. Overall, incidence tends to increase with age, so it is diagnosed more often from middle age onward, but certain subtypes can also occur in young people or children. Therefore, it is difficult to rule out the possibility based on age alone, and if there are "persistent symptoms," evaluation is needed regardless of age. By sex, many reports show it is slightly more common in men, but this is not a decisive criterion for determining whether an individual has the disease.

Incidence and the common subtypes may differ somewhat by country, region, and race. This may reflect not only genetic background but also differences in patterns of infection exposure, the distribution of immune-related diseases, access to medical care, and diagnostic classification systems. It is also epidemiologically important that non-Hodgkin lymphoma is not a disease that arises only in the lymph nodes. Because it can begin in or invade organs outside the lymph nodes, such as the stomach, intestines, skin, brain, testes, and nasal cavity, its symptoms are very diverse, and therefore the timing of diagnosis and the route of discovery can differ greatly from person to person.

The epidemiology of non-Hodgkin lymphoma is structured not as "the prevalence of a single disease" but as "multiple subtypes, each existing at a different frequency." Slowly progressing subtypes can be controlled while living with them for a long time, but relapse and retreatment may repeat; rapidly progressing subtypes can worsen sharply if untreated, but if they respond well to standard treatment, a cure can even be expected.

Therefore, understanding the disease only through numbers such as overall incidence or survival rate can lead to misunderstanding, and the subtype and stage must be considered together. Because of these characteristics, in clinical practice "how soon treatment is needed after diagnosis" is judged by subtype and stage; in some cases immediate treatment is needed, whereas in others observation may be appropriate.

Pathogenesis

The pathogenesis of non-Hodgkin lymphoma can be summarized as "a state develops in which lymphocytes keep multiplying without stopping," but the process involves several intertwined steps. Lymphocytes multiply when they encounter an infection and are regulated so that most of them disappear (apoptosis) when their task is finished. However, when changes occur in the genetic information of lymphocytes, growth signals may become excessive, or the cells may fail to die when they should, so that abnormal cells remain. If those cells then selectively survive and keep multiplying, cancer develops.

The first axis is genetic change. Chromosomal rearrangements can occur in lymphocytes during division and maturation, and B cells in particular carry out gene rearrangement in the process of producing antibodies. If mistakes occur in this process, genes that regulate growth and survival can function abnormally. The second axis is the environment. If immunity is weak, or lymphocytes are continuously stimulated by chronic inflammation or infection, the likelihood increases that these abnormal cells will not be eliminated but will survive and gradually multiply.

As the cancer cells multiply, the lymph nodes first enlarge and may be felt as lumps. Because lymph nodes are places where immune cells gather, a mass forms relatively easily once proliferation begins inside them. The cancer cells can then spread along the lymph flow and bloodstream to other lymph nodes, the spleen, liver, bone marrow, gastrointestinal tract, and elsewhere. When the bone marrow is invaded, production of normal blood cells is disrupted, which can cause anemia, susceptibility to infection, and a bleeding tendency.

Growth rate and pattern of invasion differ by subtype: some subtypes progress gradually over several years, while others grow sharply within a few weeks and can create emergency situations. Therefore, it is correct to understand the pathogenesis not as fixed to "a single pathway" but as various genetic changes and immune environments combining in different ways for each subtype.

Symptoms

The symptom most commonly mentioned in non-Hodgkin lymphoma is painless lymph node enlargement. Lumps may be felt in the neck, armpits, groin, and elsewhere; they are usually painless and may persist for more than 2 weeks or gradually grow even without a clear cause such as a cold. However, because lymph nodes commonly enlarge from infection or inflammation alone, having a lump does not immediately mean cancer. What matters is that "an unexplained condition persists."

Systemic symptoms are also important, and medical staff pay particular attention to fever of unknown cause, night sweats heavy enough to require changing clothes, and unintentional weight loss. These three are often called "B symptoms" and serve as clues for gauging disease activity. In addition, fatigue, loss of appetite, generalized weakness, itching, and skin rash may accompany the disease.

Because non-Hodgkin lymphoma can invade organs outside the lymph nodes, symptoms appear in diverse ways depending on the organ. If a mass forms in the chest, cough, chest pain, and shortness of breath can occur, and with abdominal involvement, abdominal pain, abdominal distension, and a feeling of fullness can appear. With gastrointestinal involvement there may be indigestion, diarrhea, and bleeding, and with skin involvement rashes or nodules may be seen.

Ultimately, lymphoma cannot be confirmed by symptoms alone, but the situation in which "lumps and systemic symptoms persist or gradually worsen even though there is no clear causative infection" is the most important signal for starting a diagnostic workup. In particular, if there are rapidly worsening symptoms such as difficulty breathing, severe abdominal pain, or neurological abnormalities, it is necessary to be evaluated without delay.

Signs

Signs are objective findings that medical staff confirm through examination and testing. On physical examination, lymph nodes may be enlarged in several places, or lumps that are firm, large, and do not shrink over time may be felt. More active evaluation is needed when multiple sites are enlarged at the same time rather than only one site, and when a lump grows quickly. However, these signs are "clues that raise suspicion," and the final diagnosis is confirmed by biopsy.

Hepatosplenomegaly, in which the liver or spleen becomes enlarged, may also be observed. When the spleen is enlarged, the upper left abdomen may feel heavy, or one may feel full after eating only a little. When the bone marrow is involved, findings such as pallor and shortness of breath due to anemia, frequent infections, and easy bruising or nosebleeds may appear. In some cases, skin lesions or increased body fluid such as ascites or pleural effusion may also accompany the disease.

Among signs that appear on testing, blood test abnormalities are important. A complete blood count (CBC) may show anemia, a decreased or increased white blood cell count, or a decreased platelet count. An elevated lactate dehydrogenase (LDH) can indirectly suggest tumor burden or tissue damage and may be used as a reference in assessing prognosis, but it too is not highly specific.

On imaging, lymph node masses, organ involvement, pleural effusion or ascites, and findings suggestive of bone marrow involvement may be observed. In some subtypes, lesion activity is conspicuously visible on positron emission tomography (PET)-based tests. When these signs come together, they lead to the conclusion that "the diagnosis must be confirmed by biopsy and the subtype classified." In other words, signs set the direction, but the last piece of the puzzle is the biopsy.

Screening

Currently, no standard screening test for the general public has been established for non-Hodgkin lymphoma. This is because, unlike colonoscopy, there is no single test that "clearly helps reduce deaths when performed regularly." Because the subtypes are so diverse and there are often no symptoms or only nonspecific symptoms early on, it is difficult to find efficiently with a single test. In addition, if screening is pursued excessively, false positives (results that come out suspicious when there is no cancer) increase, which can lead to unnecessary tests and anxiety.

That does not mean early detection is impossible. The realistic strategy is "symptom-based early evaluation" and "vigilance in high-risk groups." It is important for people receiving immunosuppressive treatment, people with HIV infection, and people with certain chronic infections or autoimmune diseases to be evaluated by medical staff without delay when there are changes such as new lumps, recurrent fever of unknown cause, night sweats, and weight loss.

For the general public as well, the most practical "screening" is noticing changes in oneself. Recording changes in the location and size of lumps and noting when and how high fevers occur, how much you sweat at night, and how much weight you have lost is very helpful during a consultation. However, constantly touching a lump to measure its size may instead provoke inflammation or increase anxiety, so rather than excessive self-examination, it is better to keep records focused on "duration and changes." It is also important to remember that if a lump persists for more than 2 weeks or unexplained systemic symptoms recur, what is needed is not screening but "an evaluation for diagnosis."

Diagnosis

The diagnosis of non-Hodgkin lymphoma usually proceeds step by step. The first step is history-taking and physical examination. The physician checks when the symptoms began, whether there was a recent possibility of infection, what medications are being taken, whether there is an immunocompromised state, and whether systemic symptoms such as fever, night sweats, and weight loss are present. On examination, the lymph nodes of the neck, armpits, and groin are palpated, and it is also checked whether the liver and spleen are enlarged.

Next, blood tests are used to evaluate the overall state of health and whether there are blood cell abnormalities. These may include a complete blood count (CBC) and peripheral blood smear, liver and kidney function tests, inflammation-related markers, and lactate dehydrogenase (LDH). Blood tests cannot "confirm" the diagnosis, but they are important baseline data for understanding the extent of the disease and the patient's overall condition and for judging the safety of treatment.

Imaging helps determine the location and extent of lesions and the stage (degree of spread). Computed tomography (CT) is widely used to comprehensively evaluate lymph node and organ involvement. In some subtypes, positron emission tomography (PET)-based tests, usually PET-CT, are useful for staging and for evaluating treatment response.

The most important test for confirming the diagnosis is biopsy. When possible, methods that obtain sufficient tissue, such as excisional lymph node biopsy, are preferred. The tissue obtained is used to classify the subtype through immunohistochemistry (IHC), flow cytometry, and genetic and chromosomal tests (e.g., FISH). A treatment plan can be made accurately only when the subtype, stage, and overall condition are established, and this diagnostic stage is directly linked to treatment choice and prognosis.

If necessary, a bone marrow examination is performed to check for bone marrow involvement, and before treatment, additional evaluations for safe treatment, such as cardiac function assessment and infection testing, are carried out.

Treatment

Treatment of non-Hodgkin lymphoma is not determined by the "disease name" alone; it differs greatly depending on which subtype it is, how far it has spread, whether it is growing quickly, whether there are symptoms, and what the patient's overall condition is. Treatment broadly combines observation, drug therapy, radiation therapy, transplantation, and advanced immunotherapy as suited to the situation. Therefore, some people start treatment right away, while others only undergo regular follow-up.

For some subtypes that progress slowly and cause no symptoms, observation (watchful waiting) may be chosen. This does not mean "not treating"; it is a strategy of monitoring regularly so as not to miss the point at which the benefit of treatment becomes clear. Conversely, for rapidly progressing subtypes or when there is organ compression or severe systemic symptoms, treatment may need to start quickly after diagnosis.

Drug therapy centers on chemotherapy, immunotherapy, and targeted therapy. In B-cell subtypes in particular, immunotherapy such as anti-CD20 monoclonal antibodies is often an important pillar. There are standard treatments that combine several drugs depending on the subtype and risk level, and the intensity and duration differ depending on whether the goal of treatment is cure or long-term control. In cases of relapse or poor response to treatment, hematopoietic stem cell transplantation may be considered together with high-intensity treatment, and in some cases advanced immunotherapy such as CAR-T is discussed.

During treatment, supportive care such as infection prevention, nutrition and physical fitness management, control of anemia and pain, and psychological support has a major impact on the ability to continue treatment and on quality of life. In particular, because the risk of infection rises while receiving treatments that lower immunity, a safety net of consulting medical staff immediately when symptoms occur is needed.

Prognosis

The prognosis of non-Hodgkin lymphoma is difficult to state in a single sentence such as "because it is non-Hodgkin lymphoma, it is like this." This is because the disease name is a broad category grouping multiple subtypes, and the rate of progression, treatment response, and relapse pattern differ greatly by subtype. Rapidly progressing subtypes can worsen within a short time if untreated, but in some cases a cure can be expected if they respond well to standard treatment. Conversely, slowly progressing subtypes can be controlled while living with them for a long time, but rather than cure, the course may involve repeated relapse and retreatment.

When assessing prognosis, the stage, overall condition, age, organs involved, blood test markers (e.g., LDH), and molecular characteristics of the subtype are considered together. This information is used to determine the intensity of treatment, predict the risk of relapse, and plan follow-up after treatment. It is realistic to understand prognosis as including not just survival rate figures but also "quality of life after treatment" and "long-term management."

Treatment response is evaluated by combining changes in symptoms, blood tests, imaging, and so on. Even after remission is achieved, follow-up observation is needed for a certain period, and regular checkups are recommended to detect relapse early and manage treatment side effects.

In the long term, problems such as infection risk, risk of second cancers, changes in cardiac function, peripheral nerve symptoms, and chronic fatigue may remain, so management is important. Therefore, it is good for explanations of prognosis to include the message that "even after treatment ends, health status is checked consistently for a certain period."

Prevention

No definite way to completely prevent non-Hodgkin lymphoma is yet known. However, practices that lower the risk are possible. The key is to reduce factors that impair immune function and to prevent infections or treat them early. For HIV infection, prevention, early diagnosis, and treatment are important, and for people who need immunosuppressive treatment, it helps to systematically carry out infection prevention and regular follow-up together with medical staff.

Because some infections are associated with specific subtypes, infection management can play a role close to prevention depending on the situation. For example, when H. pylori infection is confirmed and there is an indication, eradication therapy can help lower the risk of stomach-related lymphoma. In addition, if there is a possibility of occupational chemical exposure, wearing protective equipment and following safety rules are necessary, and as a principle, unnecessary radiation exposure should be reduced.

It has not been established that lifestyle directly prevents non-Hodgkin lymphoma, but basic lifestyle management that does not harm immune health, such as sleep, nutrition, exercise, not smoking, and managing chronic diseases, helps protect overall health.

Above all, "the action closest to prevention" is early evaluation. Seeing a doctor when there are changes such as a lymph node lump that persists for more than 2 weeks or grows, fever of unknown cause, night sweats, or unintentional weight loss is the most realistic way to reduce risk.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.